Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 15;200(2):160-167.
doi: 10.1164/rccm.201902-0431CI.

Patient Registries in Idiopathic Pulmonary Fibrosis

Affiliations
Review

Patient Registries in Idiopathic Pulmonary Fibrosis

Daniel A Culver et al. Am J Respir Crit Care Med. .

Abstract

Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established. These registries are collecting a wealth of longitudinal data on thousands of patients with this rare disease. The data collected in these registries will be complementary to data collected in clinical trials because the patient populations studied in registries have a broader spectrum of disease severity and comorbidities and can be followed for a longer period of time. Maintaining the quality and completeness of registry databases presents administrative and resourcing challenges, but it is important to ensuring the robustness of the analyses. Data from patient registries have already helped improve understanding of the clinical characteristics of patients with IPF, the impact that the disease has on their quality of life and survival, and current practices in diagnosis and management. In the future, analyses of biospecimens linked to detailed patient profiles will provide the opportunity to identify biomarkers linked to disease progression, facilitating the development of precision medicine approaches for prognosis and therapy in patients with IPF.

Keywords: biomarkers; interstitial lung diseases; observational study; pulmonary fibrosis.

PubMed Disclaimer

Comment in

References

    1. Council of the European Union. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) Official Journal of the European Union. 2009;C151:7–10.
    1. Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD, et al. Code-based diagnostic algorithms for idiopathic pulmonary fibrosis: case validation and improvement. Ann Am Thorac Soc. 2017;14:880–887. - PMC - PubMed
    1. Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50:1701209. - PubMed
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis. Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68. - PubMed

Publication types